Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €149.34 EUR
Change Today -1.14 / -0.76%
Volume 19.0
UTH On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 12:50 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1040 Spring Street

Silver Spring, MD 20910

United States

Phone: 301-608-9292

Fax: 301-608-9291

United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. Products and Product Candidates The company’s key therapeutic products and product candidates include the following: Prostacyclin Analogues Prostacyclin analogues are stable synthetic forms of prostacyclin, an important molecule produced by the body that has powerful effects on blood vessel health and function. The company’s main product is Remodulin (treprostinil) Injection (Remodulin), which is administered subcutaneously (under the skin) or intravenously (in the vein) for the treatment of pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise. The United States Food and Drug Administration (FDA) approved Remodulin for subcutaneous and intravenous administration in 2002 and 2004, respectively. Outside the United States, Remodulin is approved in 39 countries, most of which have approved both routes of administration. The company is in the process of developing new technologies to make Remodulin delivery more convenient, such as implantable pump systems for intravenous Remodulin and pre-filled, semi-disposable pumps for subcutaneous Remodulin. In 2009, the FDA approved Tyvaso (treprostinil) Inhalation Solution (Tyvaso), an inhaled prostacyclin therapy for the treatment of PAH to improve exercise ability. In 2013, the FDA approved Orenitram (treprostinil) Extended-Release Tablets (Orenitram), which commenced sales during 2014. The company’s wholly-owned subsidiary, Lung Biotechnology Inc. is in the process of developing another oral prostacyclin analogue for the treatment of PAH called esuberaprost. Phosphodiesterase Type 5 (PDE-5) Inhibitor PDE-5 inhibitors act to inhibit the degradation of cyclic guanosine monophosphate (cyclic GMP) in cells. Cyclic GMP is activated by nitric oxide (NO), a naturally occurring substance in the body that mediates the relaxation of vascular smooth muscle. The company’s PDE-5 inhibitor is Adcirca (tadalafil) tablets (Adcirca), a once-daily oral therapy for the treatment of PAH. The company acquired exclusive U.S. commercialization rights to Adcirca from Eli Lilly and Company (Lilly) in 2008. In 2009, the FDA approved Adcirca for the treatment of PAH to improve exercise ability. Monoclonal Antibody (MAb) MAbs act by targeting tumor-associated antigens located on the surfaces of cancer cells to activate a patient's immune system against the cancer cells. The company is in the process of developing the antibody Ch14.18 MAb for the treatment of neuroblastoma, under an agreement with the National Cancer Institute (NCI) of the United States National Institutes of Health (NIH). In December 2013, its marketing authorization application (MAA) for this antibody was accepted for review by the European Medicines Agency (EMA), and in June 2014, the FDA accepted its biologics license application (BLA) for review. Glycobiology Antiviral Agents Glycobiology antiviral agents are a novel class of small, sugar-like molecules that have shown preclinical indications of efficacy against a range of viruses. In 2011, the company was awarded a contract from the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH for studies directed at the development of an antiviral drug based on its glycobiology antiviral platform. During 2014, the company commenced a phase I clinical trial of its lead antiviral candidate, an alpha-glucosidase inhibitor called UV-4B. Cell-Based Therapy In 2011, the company entered into a license agreement with Pluristem Ltd. (Pluristem) to develop and commercialize its cell-based product, known as PLacental eXpanded (PLX) cells for the treatment of PAH. The company commenced a phase I clinical study in Australia in 2013. Lung Transplantation Using the xenotransplantation technology the company acquired through its acquisition of Revivicor Inc. (Revivicor) and other regenerative medicine technologies that the company has licensed, the company is in the early preclinical stage of developing eng

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UTH:GR €149.34 EUR -1.14

UTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.142.60 CHF -1.00
Alexion Pharmaceuticals Inc $198.41 USD -0.35
Celanese Corp $65.61 USD +0.03
Nippon Shinyaku Co Ltd ¥4,040 JPY -25.00
Vertex Pharmaceuticals Inc $132.44 USD +6.82
View Industry Companies
 

Industry Analysis

UTH

Industry Average

Valuation UTH Industry Range
Price/Earnings 50.7x
Price/Sales 5.7x
Price/Book -- Not Meaningful
Price/Cash Flow 44.3x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNITED THERAPEUTICS CORP, please visit www.unither.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.